146 related articles for article (PubMed ID: 7717154)
1. [Clinical experience with the treatment of metastatic renal cell carcinoma with subcutaneous interleukin-2r (IL-2r) and interferon Alpha-2b (IFN Alfa-2b)].
Olivier C; Carballido J; Lao AH; Gimeno A; Martín C; Renjifo D; Ondina LM; Manzano L; Alvarez-Mon M
Actas Urol Esp; 1995 Jan; 19(1):16-26. PubMed ID: 7717154
[TBL] [Abstract][Full Text] [Related]
2. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
Gause BL; Sznol M; Kopp WC; Janik JE; Smith JW; Steis RG; Urba WJ; Sharfman W; Fenton RG; Creekmore SP; Holmlund J; Conlon KC; VanderMolen LA; Longo DL
J Clin Oncol; 1996 Aug; 14(8):2234-41. PubMed ID: 8708712
[TBL] [Abstract][Full Text] [Related]
4. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
[TBL] [Abstract][Full Text] [Related]
5. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.
Alatrash G; Hutson TE; Molto L; Richmond A; Nemec C; Mekhail T; Elson P; Tannenbaum C; Olencki T; Finke J; Bukowski RM
J Clin Oncol; 2004 Jul; 22(14):2891-900. PubMed ID: 15254058
[TBL] [Abstract][Full Text] [Related]
6. The prognostic significance of immune changes in patients with renal cancer, melanoma and colorectal cancer, treated with interferon alpha 2b.
Tsavaris N; Baxevanis C; Kosmidis P; Papamichael M
Cancer Immunol Immunother; 1996 Oct; 43(2):94-102. PubMed ID: 8954143
[TBL] [Abstract][Full Text] [Related]
7. A randomized study of low-dose interleukin-2 subcutaneous immunotherapy versus interleukin-2 plus interferon-alpha as first line therapy for metastatic renal cell carcinoma.
Lissoni P; Barni S; Ardizzoia A; Andres M; Scardino E; Cardellini P; Della Bitta R; Tancini G
Tumori; 1993 Dec; 79(6):397-400. PubMed ID: 8171738
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma.
Verra N; Jansen R; Groenewegen G; Mallo H; Kersten MJ; Bex A; Vyth-Dreese FA; Sein J; van de Kasteele W; Nooijen WJ; de Waal M; Horenblas S; de Gast GC
Br J Cancer; 2003 May; 88(9):1346-51. PubMed ID: 12778059
[TBL] [Abstract][Full Text] [Related]
10. Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma.
Motzer RJ; Rakhit A; Thompson JA; Nemunaitis J; Murphy BA; Ellerhorst J; Schwartz LH; Berg WJ; Bukowski RM
J Interferon Cytokine Res; 2001 Apr; 21(4):257-63. PubMed ID: 11359657
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma.
Atkins MB; Sparano J; Fisher RI; Weiss GR; Margolin KA; Fink KI; Rubinstein L; Louie A; Mier JW; Gucalp R
J Clin Oncol; 1993 Apr; 11(4):661-70. PubMed ID: 8478661
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous interleukin-2 and interferon-alpha 2b in patients with metastatic renal cell cancer: the German outpatient experience.
Kirchner H; Körfer A; Palmer PA; Evers P; De Riese W; Knüver-Hopf J; Hadam M; Goldman U; Franks CR; Poliwoda H
Mol Biother; 1990 Sep; 2(3):145-54. PubMed ID: 2222898
[TBL] [Abstract][Full Text] [Related]
13. The prognostic significance of immune changes in patients with renal cell carcinoma treated with interferon alfa-2b.
Kosmidis PA; Baxevanis CN; Tsavaris N; Papanastasiou M; Anastasopoulos E; Bacoyiannis C; Mylonakis N; Karvounis N; Bafaloukos D; Karabelis A
J Clin Oncol; 1992 Jul; 10(7):1153-7. PubMed ID: 1535102
[TBL] [Abstract][Full Text] [Related]
14. [Immunotherapy with low-dose subcutaneous interleukin-2 in metastatic renal carcinoma].
Lissoni P; Barni S; Tancini G; Andres M; Scardino E; Cardellini P; Frascaroli M; Ardizzoia A; Crispino S; Vicini D
Arch Ital Urol Androl; 1993 Apr; 65(2):123-8. PubMed ID: 8330055
[TBL] [Abstract][Full Text] [Related]
15. Standard interleukin-2 (IL-2) and interferon-alpha immunotherapy versus an IL-2 and 4-epirubicin immuno-chemotherapeutic association in metastatic renal cell carcinoma.
Naglieri E; Gebbia V; Durini E; Lelli G; Abbate I; Selvaggi FP; Di Tonno P; Colucci G
Anticancer Res; 1998; 18(3B):2021-6. PubMed ID: 9677460
[TBL] [Abstract][Full Text] [Related]
16. Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies.
Atzpodien J; Körfer A; Franks CR; Poliwoda H; Kirchner H
Lancet; 1990 Jun; 335(8704):1509-12. PubMed ID: 1972442
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of interferon-gamma versus interleukin-2 and interferon-alpha 2b in metastatic renal cell carcinoma.
Lümmen G; Goepel M; Möllhoff S; Hinke A; Otto T; Rübben H
J Urol; 1996 Feb; 155(2):455-8. PubMed ID: 8558634
[TBL] [Abstract][Full Text] [Related]
18. Low-dose intravenous bolus interleukin-2 with interferon-alpha therapy for metastatic melanoma and renal cell carcinoma.
Karp SE
J Immunother; 1998 Jan; 21(1):56-61. PubMed ID: 9456437
[TBL] [Abstract][Full Text] [Related]
19. The prognostic significance of immune changes in patients with renal cancer and melanoma treated with interferon-alpha 2b.
Tsavaris N; Baxevanis K; Kosmidis P; Papamichael M
Tumour Biol; 1995; 16(6):365-73. PubMed ID: 7569683
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie.
Ravaud A; Delva R; Gomez F; Chevreau C; Douillard JY; Peny J; Coudert B; Négrier S;
Cancer; 2002 Dec; 95(11):2324-30. PubMed ID: 12436438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]